ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment

by Ruibin Yi, Anqi Lin, Manming Cao, Abai Xu, Peng Luo, Jian Zhang
Published 2020-08-01

Glycogen Metabolism Predicts the Efficacy of Immunotherapy for Urothelial Carcinoma

by Yueming Zhang, Xuechun Li, Rui Zhou, Anqi Lin, Manming Cao, Qingwen Lyu, Peng Luo, Jian Zhang
Published 2021-08-01

Influence of Different Age Cutoff Points on the Prediction of Prognosis of Cancer Patients Receiving ICIs and Potential Mechanistic Exploration

by Rui Guan, Qiong Lyu, Anqi Lin, Junyi Liang, Weimin Ding, Manming Cao, Peng Luo, Jian Zhang
Published 2021-06-01

Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition

by Qiong Lyu MD, Anqi Lin MD, Manming Cao MD, Abai Xu MD, Peng Luo MD, Jian Zhang MD
Published 2020-12-01

Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma

by Chaozheng Zhou, Chaozheng Zhou, Anqi Lin, Manming Cao, Weimin Ding, Weiming Mou, Weiming Mou, Ningyi Guo, Zhenyu Chen, Jian Zhang, Peng Luo
Published 2021-06-01